Here are three things to know.
1. Austedo is intended to treat chorea — an involuntary movement disorder — associated with Huntington’s. Ninety percent of patients with the disease experience chorea.
2. The drug represents the second FDA-approved treatment for Huntington’s.
3. Teva said the drug will be available in the next three weeks.
More articles on supply chain:
11 drugs on FDA’s new safety alert list
How SSM Health’s pharmacy concierge program helps patients manage high drug costs
Sanofi agrees to pay $20M for overcharging VA for vaccines: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
